SCHEMBL1161534

SCHEMBL1161534

O=Cc1cc2cccnc2cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.47
▸ POLB P06746 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ ALDH1A1 P00352 6/20 0.44
▸ MAPT P10636 3/20 0.44
▸ HTT P42858 3/20 0.44
▸ CASP1 P29466 2/20 0.44
▸ ATM Q13315 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ ERN1 O75460 1/20 0.44
▸ PDGFRB P09619 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TRIM24 O15164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169868 0.93 NPC1 (0.47) NPC1POLBRAB9AALDH1A1MAPT
Hydrochloric Acid SCHEMBL29870040 0.81 NPC1 (0.46) NPC1POLBRAB9AALDH1A1MAPT
Hydrochloric Acid SCHEMBL28864731 0.81 NPC1 (0.46) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL29954584 0.79 MEN1 (0.50) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL3412523 0.79 CASP6 (0.57) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL5833750 0.79 NPC1 (0.54) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL3410524 0.79 NPC1 (0.43) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL27976819 0.79 NPC1 (0.45) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL21816095 0.77 ERN1 (0.37) ALDH1A1MAPTHTTKDM4EHSD17B10
SCHEMBL9807462 0.76 MEN1 (0.50) NPC1POLBRAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559504-B2 Benzotriazole derivative UBE CORPORATION (JP) 2026-02-24 — — US disclosed
EP-3978073-B1 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES UBE CORP (JP) 2025-10-15 — — EP disclosed
WO-2025132870-A1 CHEMICAL COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) 2025-06-26 — — WO disclosed
CN-114174289-B Benzotriazole derivatives UBE株式会社 2025-03-07 — — CN disclosed
CN-115703766-A GLP-1 receptor agonists and uses thereof 天地恒一制药股份有限公司 2023-02-17 — — CN disclosed
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2022-08-18 — — US disclosed
EP-3978073-A1 BENZOTRIAZOLE DERIVATIVE Ube Industries, Ltd. (JP) 2022-04-06 — — EP disclosed
CN-114174289-A Benzotriazole derivatives 宇部兴产株式会社 2022-03-11 — — CN disclosed
WO-2020241853-A1 BENZOTRIAZOLE DERIVATIVE 宇部興産株式会社 2020-12-03 — — WO disclosed
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 — — US disclosed
US-20110039831-A1 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES NOVARTIS AG (CH) 2011-02-17 — — US disclosed
WO-2011018454-A1 HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION NOVARTIS AG (CH) 2011-02-17 — — WO disclosed
WO-2011015652-A1 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS NOVARTIS AG (CH) 2011-02-10 — — WO disclosed
WO-2011015652-A1 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS NOVARTIS AG (CH) 2011-02-10 — — WO disclosed
EP-2265614-A1 IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE Novartis AG (CH) 2010-12-29 — — EP disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559504-B2 Benzotriazole derivative KEAP1, NFE2L2, NCOR1 NPC1 378/4885POLB 3634/4885RAB9A 4258/4885
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK NPC1 4172/4885POLB 4269/4885RAB9A 3328/4885
US-20110039831-A1 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES MET, ERBB2, ABL1 NPC1 3580/4885POLB 4690/4885RAB9A 2644/4885
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE KEAP1, NFE2L2, BACH1 NPC1 381/4885POLB 3011/4885RAB9A 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback